New eye drop offers hope for those let down by common dry eye medication
NCT ID NCT07267299
Summary
This study is for adults with chronic dry eye who are currently using Restasis eye drops but are not satisfied with the results. Researchers want to see if switching to a newer, FDA-approved drop called TRYPTYR (acoltremon) can better improve symptoms like dryness and burning, and increase tear production. The study will measure changes in symptoms and eye wetness over 28 days after the switch.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.